Quick Answer
Why weak laws, slow laboratories, customs limitations, and jurisdiction gaps prevent governments from stopping counterfeit products alone.
Back to Blog
GOVERNMENT
15 min read
Where the State Falls Short: Weak Laws, Slow Labs, and the Public-Sector Failure to Stop Counterfeit Products
Why weak laws, slow laboratories, customs limitations, and jurisdiction gaps prevent governments from stopping counterfeit products alone.
Where the State Falls Short: Weak Laws, Slow Labs, and the Public-Sector Failure to Stop Counterfeit Products
Government
Why weak laws, slow laboratories, customs limitations, and jurisdiction gaps prevent governments from stopping counterfeit products alone.
QUICK ANSWER
Why weak laws, slow laboratories, customs limitations, and jurisdiction gaps prevent governments from stopping counterfeit products alone.
Introduction: A Crime the State Is Not Built to Catch
Every counterfeit-product story begins and ends with the state. It is the state that writes the laws against fraud, runs the customs offices that inspect imports, operates the forensic laboratories that test seized goods, prosecutes the criminals, and when it works protects the consumer from buying poison instead of medicine.
But for almost the entire history of counterfeiting, the state has been running behind. The Bradford sweets poisoning of 1858 killed 20 people and injured over 200, and all three defendants were acquitted because no law had been broken. The 1937 Elixir Sulfanilamide disaster killed 107 Americans, and the only legal violation the manufacturer could be charged with was misbranding a technicality that drew the minimum fine. The 2024 counterfeit Botox outbreak hospitalised 11 women across 11 U.S. states before the FDA could even issue its alert. The 2026 Delhi raid on a counterfeit-protein-supplement unit happened only after the operation had already been running long enough to accumulate 100 kg of finished fake product.
The pattern is consistent. Counterfeiting evolves. The state’s response lags.
This article is a structural diagnosis of why examining the weaknesses in laws, penalties, customs detection, laboratory testing, and international coordination that together explain why the public sector is no longer the front-line defence consumers think it is. It closes by outlining the specific, evidence-based reforms governments need to make, and the role that modern product-level authentication must play alongside them.
Section 1 The Laws Don’t Match the Crime
The single most important structural weakness in counterfeit enforcement is that the laws underlying it were mostly written before the world looked the way it does now.
In most jurisdictions, counterfeit enforcement still relies on a combination of:
Two structural gaps emerge from this patchwork:
The result is that the law often arrives too late, in the wrong jurisdiction, or against the wrong target. Counterfeiters know this. They design their operations around it.
Trademark law which protects brand owners but requires a trademark holder to take action, often through lengthy civil litigation.
Customs law which empowers border seizure but typically punishes the importer, not the manufacturer in a third country.
Consumer-protection law which addresses misleading marketing and product safety but rarely targets the production of counterfeits at scale.
Criminal fraud statutes which apply but were written for individual fraudsters, not transnational counterfeit factories.
-
Cross-border manufacturers are nearly untouchable. A counterfeit factory in a free-trade zone outside the EU or U.S. can manufacture millions of fake bars, vials, or tubs, ship them through a transit country, and have them delivered to consumers in 50 nations and at no point in that journey does any single national law-enforcement agency have practical jurisdiction over the manufacturer itself.
-
Trademark protection is not the same as consumer protection. “Dubai Chocolate” cannot be trademarked as a name because, as one legal analysis on the case noted, intellectual-property offices generally do not allow registration of descriptive names combining a place and a product type. So even when a counterfeit copies a viral product in every meaningful way, the original creator may have little legal recourse against those producing similar bars.
Section 2 Weak Penalties (Bradford to Today)
Even where laws do apply, the penalties have historically been too low to deter.
The historical record is a near-comic catalogue of mismatched punishments. In 1858 in Bradford, after twenty people died from arsenic-laced sweets, all three men involved were charged with manslaughter and all three were acquitted because the existing law was too ambiguous to prove criminal liability. The disaster led to the Adulteration of Food or Drink Act of 1860, the Pharmacy Act of 1868, and eventually the Sale of Food and Drugs Act of 1875 but the legislation passed was widely criticised at the time for being too ambiguous and for setting penalties too low to act as a deterrent.
In 1937, after 107 Americans (a third of them children) died from Elixir Sulfanilamide poisoned with diethylene glycol, S.E. Massengill paid only the minimum fine for misbranding under the 1906 Pure Food and Drug Act. The substantive reform the 1938 Federal Food, Drug, and Cosmetic Act only happened after a national scandal forced Congress’s hand.
The pattern continues today. U.S. CBP guidance lists criminal penalties for trafficking counterfeit goods at up to $2 million and 10 years in prison, which sounds substantial, but the typical outcome is administrative seizure and forfeiture rather than criminal prosecution. Most counterfeit operations are run from jurisdictions that the U.S. cannot reach. The serious deterrent applies only to importers caught at the border a small fraction of the actual offenders.
The UAE, by contrast, has some of the strictest cybercrime and counterfeit-fraud penalties in the world fines of AED 250,000 to 1 million plus imprisonment, business shutdown, and licence revocation under federal regulations. Yet even there, the enforcement pipeline is limited by the same structural problem: investigating, prosecuting, and convicting counterfeiters requires far more resources than most public agencies can sustain at scale.
The Authentication Solution Providers’ Association (ASPA) estimates that counterfeiting causes losses of more than ₹1 trillion per year to the Indian economy and $16.2 billion per year in tax revenue. The total criminal-justice budget directed at countering this crime in India is a tiny fraction of those losses. The economics simply do not balance.
Section 3 Slow Detection: The Laboratory Bottleneck
Even when a suspected counterfeit is seized, the state’s ability to confirm that it is fake and to prove it in court depends on a forensic laboratory infrastructure that is, in most countries, dramatically under-resourced and slow.
Customs laboratory testing, used to verify whether seized goods are counterfeit or unsafe, involves chemical, physical, and microbiological analyses that can take days to weeks per sample. As one industry analysis notes, testing procedures can be time-consuming, resulting in delays in product clearance or release, and not all countries have well-equipped customs laboratories capable of conducting specific testing procedures, which often means samples must be sent to external laboratories, adding costs and further time.
The broader forensic-laboratory ecosystem is in even worse shape. According to data analysed by the National Institute of Justice, U.S. forensic laboratories had an estimated backlog of 570,100 requests for all forensic services at the end of 2014, with fingerprint cases alone running at 55.53% backlog in 2019–2020. The U.S. Department of Justice’s 2005 census found high percentages of backlogged cases defined as those not completed within thirty days across nearly every forensic discipline. In 2025, state and local crime labs were reported to be “drowning in evidence,” with some labs facing years-long backlogs across DNA, ballistics, and other case categories.
Counterfeit-product testing competes with violent crime, drug-investigation, and DNA casework for the same laboratory resources. In any conflict over priorities, counterfeit testing loses. The result is that even when customs seizes a suspected fake, the legal case against it may not be ready for months long after the rest of the same counterfeit batch has already been sold to consumers somewhere else in the world.
The mismatch is structural. A counterfeiter can produce 100,000 fake units in a week. A forensic laboratory may need several weeks to chemically authenticate a single one.
Section 4 The Inspection Reality: 90% of Counterfeits Are Now Invisible to Customs
The single most important change in the geography of counterfeiting over the past decade has rendered most twentieth-century customs infrastructure obsolete.
According to U.S. CBP itself, over 90% of all counterfeit seizures now occur in the international mail and express-courier environments, not in container cargo. The OECD’s 2021 report on combating trafficking in counterfeit goods explicitly notes that small parcels are harder to detect than shipping containers because container cargo arrives with extensive paperwork well in advance of port arrival, while small parcels do not.
The economics of this are brutal. As the U.S. Government Accountability Office documented in its 2020 report on small-package counterfeiting:
The structural truth this data exposes is uncomfortable but unavoidable: the volume of small-parcel e-commerce has decisively outgrown the capacity of every major customs authority in the world. CBP, the European Commission, and EUIPO have all said as much, in print.
This is not a problem any government can solve by hiring more inspectors. The economics do not work. A different approach is required.
CBP processes roughly 1.8 million small packages per day sent via international mail and express carriers.
The effort required for CBP to seize a small-package shipment is essentially the same as the effort required to seize a cargo container but the inspector recovers a tiny fraction of the counterfeit volume per inspection.
EU and U.S. customs officials report common challenges in combating small-package counterfeit flow, including inadequate data on the packages and the need to prioritise inspection resources among competing demands like drug enforcement, security threats, and forced-labour goods.
In one GAO-led test, 20 of 47 items purchased from third-party sellers on major e-commerce platforms turned out to be counterfeit including makeup and consumer goods.
Section 5 International Coordination Gaps
Counterfeiting is the most international of crimes. Counterfeit enforcement, by contrast, remains stubbornly national.
The structural gaps include:
The result is that counterfeit networks systematically exploit the seams between jurisdictions. The OECD–EUIPO 2025 Mapping Global Trade in Fakes report identifies this directly: counterfeiters increasingly use “localisation” strategies, shipping unassembled parts or packaging to assemble fake products closer to end markets, and exploit free-trade zones with reduced oversight as routing hubs.
The Universal Postal Union’s reimbursement rates have, for decades, underpriced domestic postage rates for small parcels entering the United States, which the U.S. Department of Homeland Security has formally identified as a contributor to the small-parcel-counterfeit surge.
In short: counterfeit networks have built global supply chains. The state’s response is still mostly national.
Different legal standards across jurisdictions. What is a criminal offence in the EU may be only a civil matter in another country. What requires a clinical trial in the U.S. may be sold over the counter elsewhere.
Different serialisation and traceability standards. Even where countries do mandate unit-level authentication for pharmaceuticals, the formats vary. As one regulatory analysis notes, the most significant practical challenge cited by global brands is the variation across markets, making a one-size-fits-all solution impossible.
Different penalty structures. A counterfeiter sentenced to ten years in one country could face only a fine in another incentivising organised crime to base operations in jurisdictions with weaker penalties.
Different enforcement priorities. Customs in one country may treat counterfeit cosmetics as a priority; another may treat them as a low-priority nuisance compared with narcotics or firearms.
Section 6 Where Governments DO Work: The Pharma Lesson
It would be unfair to suggest that the state cannot succeed against counterfeit products. In one specific category pharmaceuticals it has succeeded, and the lessons are clear.
The U.S. Drug Supply Chain Security Act (DSCSA) of 2013 mandated full electronic interoperable serialisation across the entire pharmaceutical supply chain. After several enforcement extensions, the system became fully enforceable from 27 May 2025.
The EU Falsified Medicines Directive (FMD), in force since 9 February 2019, requires a tamper-evident feature and a 2D DataMatrix code on every prescription pack, with verification at the point of dispense via the European Medicines Verification System.
As of 2026, more than 78 countries worldwide mandate serialisation and traceability compliance for pharmaceutical products including Russia, China, India, Japan, South Korea, Türkiye, Saudi Arabia, and the UAE (via the Tatmeen platform).
And it works. A case study from Nigeria’s pharmaceutical sector documented a reduction in counterfeit rates for some key medicines from nearly 20% to 3.5% within three years after coordinated deployment of physical and digital authentication, track-and-trace, enforcement, and consumer awareness.
The pharmaceutical model proves that the state can break the back of a counterfeit problem when it:
The challenge is that this template has not yet been extended to the categories where it is now most needed: cosmetics, injectables, dietary supplements, premium food, and high-value electronics.
-
Mandates unit-level authentication at the manufacturer.
-
Requires verification at the point of dispense or sale.
-
Standardises on a single technical standard (GS1).
-
Gives industry a multi-year stabilisation period to implement.
-
Pairs the mandate with criminal-law backing and customs enforcement.
Section 7 What Governments Should Actually Do
Building on the public record, six concrete reforms emerge as the highest-leverage actions governments can take.
1. Extend pharma-style mandates to high-risk consumer categories
Cosmetics (China’s NMPA already moved here in 2021), injectables, dietary supplements, infant formula, and premium food categories are the obvious next candidates. The 2024 counterfeit-Botox hospitalisations and the chronic heavy-metal contamination in protein powders are exactly the kind of public-health events that historically precede regulatory mandates.
2. Increase penalties to the level of organised crime, not petty fraud
Penalties for industrial counterfeiting need to be calibrated against the economic value of the crime, not the value of the seized batch. UAE-style penalty structures (AED 250,000–1,000,000 plus imprisonment, business shutdown, licence revocation) are the right model.
3. Fund customs laboratories and forensic labs adequately
Without faster authentication testing, every seizure becomes a months-long bottleneck. Governments need to treat customs and forensic labs the way they treat security infrastructure not as discretionary line items but as core public-safety capacity.
4. Reform the small-parcel inspection model
The current customs paradigm assumes container shipping. Reform options include lowering the de-minimis inspection threshold, requiring electronic advance data on small parcels, and shifting enforcement weight from border interdiction to platform-level enforcement against e-commerce marketplaces.
5. Harmonise traceability standards internationally
The convergence on GS1 standards in pharmaceutical serialisation is the model. Extending the same harmonisation across cosmetics, supplements, and food would dramatically reduce the cross-jurisdictional gaps that counterfeit networks currently exploit.
6. Make the manufacturer co-responsible
Most enforcement still treats authentication as something the brand must do voluntarily. Where consumer-safety harm is foreseeable, the legal framework should require it just as pharmaceutical premarket safety testing has been required since 1938.
Section 8 Why Government Alone Will Never Be Enough
Even with every one of the reforms above, government enforcement will always run behind the counterfeit market. The reasons are structural:
The only structural answer is to move authentication closer to the consumer to bind it to the product itself, and let any buyer anywhere verify in real time. This is what pharmaceutical serialisation already does within the regulated drug supply chain. The same logic is what modern product-authentication platforms including TrustQR are now extending to every consumer-product category.
The state must do its part. It must update its laws, increase its penalties, fund its labs, reform its inspection models, and harmonise its standards across borders. But governments alone even the best-run, best-resourced governments in the world cannot keep up with a $467-billion global crime that has restructured itself around the gaps in their enforcement.
What can keep up is a system in which every product unit carries its own verifiable identity, and the consumer at the point of purchase has the same authentication capability the customs officer at the border does. That is the structural answer to the structural problem.
The 1858 Bradford sweets case ended without a single conviction because the law had not caught up to the crime. Almost 170 years later, in too many product categories, that gap still exists. Closing it requires the state to do what it has always done pass laws, fund labs, prosecute offenders but it also requires the rest of us to stop expecting the state alone to solve a problem the state is structurally incapable of solving by itself.
Counterfeiters move faster than legislatures. A new viral product can be cloned and sold worldwide within weeks; mandating its authentication requires regulatory consultation, draft legislation, comment periods, and stabilisation timelines that often run to years.
Enforcement is reactive by design. The FDA’s counterfeit-Botox alert came after eleven hospitalisations. The Delhi raid happened after the counterfeit unit had been operating long enough to accumulate industrial volumes. The state, by definition, responds to a problem after a complaint or an investigation reveals it.
The economics of inspection are fixed. Whatever the state can afford to inspect, the counterfeit market will exceed.
Sources & Further Reading
These external references support the article topic and help readers verify the broader research context behind product verification, counterfeit risk, consumer safety, or supply chain protection.
U.S. Department of Homeland Security, Combating Trafficking in Counterfeit and Pirated Goods, 2020
U.S. Government Accountability Office, INTELLECTUAL PROPERTY: CBP Has Taken Steps to Combat Counterfeit Goods in Small Packages, GAO-20-692
U.S. Customs and Border Protection, The Truth Behind Counterfeits (90% of seizures in small parcels and express courier)
U.S. CBP, Penalties Program
eCFR, 19 CFR Part 171 Fines, Penalties, and Forfeitures
OECD–EUIPO, Mapping Global Trade in Fakes 2025
eCustomsClearing, What Is A Customs Laboratory Testing, And What Products Does It Test?
Adams and Reese, Procedures and Strategies for Anti-Counterfeiting: United States (seven-day CBP detention waiting period)
Wikipedia, 1858 Bradford sweets poisoning (acquittals because no law had been broken)
U.S. FDA, The Sulfanilamide Disaster (Massengill misbranding fine)
U.S. FDA, Counterfeit Version of Botox Found in Multiple States, April 16, 2024
CDC, Adverse Effects Linked to Counterfeit or Mishandled Botulinum Toxin Injections, HAN-00507, April 23, 2024
Connecticut General Assembly Office of Legislative Research, Forensic Testing Turnaround Times in 50 States
ScienceDirect, The effects and benefits of a latent print AFIS deferral policy (570,100 U.S. forensic backlog 2014; 55.53% fingerprint backlog 2019-20)
Stateline, Forensic crime labs are buckling as new technology increases demand (2025)
The Law Reporters, Rise in Scams Through Fake Websites and Counterfeiting Impacting Dubai’s Market (UAE penalty framework)
ASPA, State of Counterfeiting in India and Nigeria pharma case study
IntuitionLabs, DSCSA vs. EU FMD: A Pharma Serialization & Traceability Guide
IntuitionLabs, FMD Explained: A Guide to Pharma Serialization & Barcodes (78+ country mandates)
SoftGroup, World map showing pharmaceutical serialization regulations by country status 2026
Steven Mather Solicitor, Dubai Chocolate, Copycats And The Limits Of Intellectual Property Law
Related TrustQR pages
Continue with the QR product verification workflow, review anti-counterfeit platform features, or compare QR code and contactless tag pricing.